{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:38:52Z","timestamp":1756384732366,"version":"3.40.4"},"reference-count":12,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,6,26]]},"abstract":"<jats:p>Merkel-cell carcinoma (MCC) is a rare but aggressive cutaneous malignancy arising most often in sun-exposed Caucasians who are immunosuppressed or the elderly. Patients with metastatic disease treated with chemotherapy have a median progression-free survival of just 3 months. This report describes a 58-year-old man with a background history of psoriasis treated with immunosuppressive therapy and subsequently diagnosed with metastatic MCC. Chemotherapy produced a partial response. Then, a novel immunotherapy agent, pembrolizumab, induced a complete response maintained for at least 19 months. Quality of life was unaffected, and toxicity from immunotherapy was minimal. At the time of writing, there was no clinical or radiological evidence of recurrence and treatment is ongoing.<\/jats:p>","DOI":"10.1136\/bcr-2018-224924","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T05:16:34Z","timestamp":1531372594000},"page":"bcr-2018-224924","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Metastatic Merkel-cell carcinoma: the dawn of a new era"],"prefix":"10.1136","volume":"2018","author":[{"given":"Timothy","family":"O\u2019Brien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek G","family":"Power","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,7,11]]},"reference":[{"key":"2025042705320841000_2018.jul10_1.bcr-2018-224924.1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/jco.2014.32.15_suppl.9091","article-title":"Response rate and durability of chemotherapy for metastatic Merkel cell carcinoma among 62 patients","volume":"32","author":"Iyer","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025042705320841000_2018.jul10_1.bcr-2018-224924.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603702"},{"key":"2025042705320841000_2018.jul10_1.bcr-2018-224924.3","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025042705320841000_2018.jul10_1.bcr-2018-224924.4","unstructured":"A Merkel cell carcinoma arising on the lower leg. www.merkelcell.org (accessed 13th June 2018)."},{"key":"2025042705320841000_2018.jul10_1.bcr-2018-224924.5","first-page":"A4464","article-title":"[Merkel cell carcinoma during treatment with TNF-alpha inhibitors: coincidence or warning?]","volume":"156","author":"Linn-Rasker","year":"2012","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2025042705320841000_2018.jul10_1.bcr-2018-224924.6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/bjd.13870","article-title":"Merkel cell carcinoma and Merkel cell polyomavirus: a systematic review and meta-analysis","volume":"173","author":"Santos-Juanes","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025042705320841000_2018.jul10_1.bcr-2018-224924.7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5858\/2009-0165-RSR2.1","article-title":"Merkel cell carcinoma","volume":"134","author":"Wong","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"2025042705320841000_2018.jul10_1.bcr-2018-224924.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.11.020"},{"key":"2025042705320841000_2018.jul10_1.bcr-2018-224924.9","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5266-4"},{"key":"2025042705320841000_2018.jul10_1.bcr-2018-224924.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2493"},{"key":"2025042705320841000_2018.jul10_1.bcr-2018-224924.11","unstructured":"Keytruda TM (pembrolizumab) Summary of Product Characteristics. www.medicines.ie (accessed 26 Nov 2017)."},{"key":"2025042705320841000_2018.jul10_1.bcr-2018-224924.12","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-05-0895"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-224924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T12:32:20Z","timestamp":1745757140000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-224924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,11]]},"references-count":12,"alternative-id":["10.1136\/bcr-2018-224924"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-224924","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2018,7,11]]}}}